37 completed. 37 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 37 | Completed 37 |
| Phase 2 | 4 | Completed 4 |
Follow Benign Prostatic Hyperplasia: new trials by email Literature Review of Benign Prostatic Hyperplasia trials Research Report on Benign Prostatic Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia DKF-313, Dutasteride, Tadalafil - Benign Prostatic Hyperplasia | Phase 3 | Completed | Dongkook Pharmaceutical Co., Ltd. | 667 | 2021-07-27 | 2023-09-21 |
| The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility Spermotrend - Male Infertility, Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | Catalysis SL | 150 | 2021-06-15 | 2023-03-28 |
| Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia Tanzânia association, Omnic Ocas, Omnic Ocas placebo - Erectile Dysfunction, Benign Prostatic Hyperplasia | Phase 3 | Completed | EMS | 295 | 2021-03-14 | 2025-12-08 |
| Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia Composite Steep-pulse Treatment Device, Tamsulosin Hydrochloride Capsules - Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | REMD Medical Technology | 160 | 2020-08-20 | 2022-09-07 |
| A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial Moses laser enucleation of prostate - Benign Prostatic Hyperplasia | Phase 3 | Completed | Vanderbilt University Medical Center | 60 | 2020-01-01 | 2022-03-31 |
| Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia Embosphere® (Prostatic Arteries Embolization), Drug therapy - Benign Prostatic Hyperplasia | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 90 | 2016-08-01 | 2022-05-03 |
| Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH Tamsulosin 0.2mg + Solifenacin 5mg, Tamsulosin 0.2mg + Placebo(Solifenacin) - Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia | Phase 3 | Completed | Jeil Pharmaceutical Co., Ltd. | 780 | 2016-02-01 | 2019-08-29 |
| Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients Tamsulosin 0.2mg, Tadalafil 5mg - Benign Prostatic Hyperplasia | Phase 3 | Completed | Chong Kun Dang Pharmaceutical | 455 | 2015-09-01 | 2017-08-11 |
| A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules HCP1303 capsule 5/0.2mg, HCP1303 capsule 5/0.4mg, HGP1201 - Benign Prostatic Hyperplasia | Phase 3 | Completed | Hanmi Pharmaceutical Company Limited | 510 | 2015-03-01 | 2016-10-13 |
| Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS Tamsulosin HCL 0.4mg, Tamsulosin HCL 0.2mg - Benign Prostatic Hyperplasia | Phase 3 | Completed | GL Pharm Tech Corporation | 309 | 2014-03-01 | 2016-02-25 |
| Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH PRX302, Placebo - Benign Prostatic Hyperplasia | Phase 3 | Completed | Sophiris Bio Corp | 479 | 2013-10-01 | 2017-04-27 |
| Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022) NX-1207 - Benign Prostatic Hyperplasia, BPH | Phase 3 | Completed | Nymox Corporation | 160 | 2013-04-01 | 2017-03-10 |
| Clinical Trial of Safety and Efficacy of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression Afalaza, Placebo - Benign Prostatic Hyperplasia | Phase 3 | Completed | Materia Medica Holding | 260 | 2012-11-01 | 2018-11-28 |
| Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH) Tadalafil, Placebo - Benign Prostatic Hyperplasia | Phase 3 | Completed | Eli Lilly and Company | 610 | 2011-12-01 | 2013-09-25 |
| Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX-1207 - Benign Prostatic Hyperplasia | Phase 3 | Completed | Nymox Corporation | 192 | 2011-09-01 | 2014-04-30 |
| Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c) MCS-2 - Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia | Phase 3 | Completed | Health Ever Bio-Tech Co., Ltd. | 200 | 2011-01-01 | 2015-03-03 |
| A Study in Benign Prostatic Hyperplasia Tadalafil, Placebo - Benign Prostatic Hyperplasia | Phase 3 | Completed | Eli Lilly and Company | 97 | 2010-09-01 | 2013-05-20 |
| A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Tadalafil, Placebo, Finasteride - Benign Prostatic Hyperplasia, Enlarged Prostate | Phase 3 | Completed | Eli Lilly and Company | 696 | 2010-09-01 | 2013-02-27 |
| Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms MCS-2 - Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia | Phase 3 | Completed | Health Ever Bio-Tech Co., Ltd. | 180 | 2010-08-01 | 2016-11-11 |
| MCS in the Treatment of Lower Urinary Tract Symptoms MCS-2 15 mg/day, MCS-2 30 mg/day, Placebo - Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | Health Ever Bio-Tech Co., Ltd. | 274 | 2010-07-01 | 2015-03-03 |
Showing 20 of 37. Sign in to see all of them.
Prostatic Hyperplasia (37) · Lower Urinary Tract Symptoms (10) · Erectile Dysfunction (2) · Urinary Bladder Neck Obstruction (2) · Genital Diseases, Male (1) · Hyperplasia (1) · Infertility, Male (1) · Prostatic Diseases (1) · Signs and Symptoms (1)
Genital Diseases (37) · Male Urogenital Diseases (37) · Urogenital Diseases (37) · Genital Diseases, Male (36) · Prostatic Diseases (36) · Pathological Conditions, Signs and Symptoms (11) · Signs and Symptoms (10) · Urological Manifestations (10) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Mental Disorders (2) · Sexual Dysfunction, Physiological (2) · Sexual Dysfunctions, Psychological (2) · Urethral Diseases (2) · Urethral Obstruction (2)
Tadalafil (10) · Tamsulosin (8) · Solifenacin Succinate (3) · fexapotide (3) · silodosin (3) · Dutasteride (2) · Finasteride (2) · Drug Therapy (1) · Duration of Therapy (1) · PRX302 (1) · alfuzosin (1) · saw palmetto extract (1)
Eli Lilly and Company (8) · Health Ever Bio-Tech Co., Ltd. (4) · Nymox Corporation (3) · Astellas Pharma Europe B.V. (2) · Sanofi (2) · Watson Pharmaceuticals (2) · Assistance Publique - Hôpitaux de Paris (1) · Catalysis SL (1) · Chong Kun Dang Pharmaceutical (1) · Dongkook Pharmaceutical Co., Ltd. (1) · EMS (1) · GL Pharm Tech Corporation (1) · GlaxoSmithKline (1) · Hanmi Pharmaceutical Company Limited (1) · Jeil Pharmaceutical Co., Ltd. (1)
United States (17) · Italy (6) · France (5) · Germany (5) · Russia (5) · South Korea (5) · Austria (3) · Belgium (3) · Canada (3) · Japan (3) · Mexico (3) · Poland (3) · Taiwan (3) · United Kingdom (3) · Argentina (2)
Allan J Pantuck, MD, MS, FACS (2) · Andrew Avins, MD, MPH (1) · Choung-Soo Kim, M.D.,Ph.D (1) · Christopher Re Chapple, BSc MD (1) · Lawrence Hill, Pharm D, RPh (1) · Lawrence Hill, PharmD, RPh (1) · Marc Sapoval, MD (1) · Myung Soo Choo, MD., Ph.D (1)
PMID 26299520, PMID 16467543, PMID 18355417, PMID 18722631, PMID 19409693, PMID 19815265, PMID 20163842, PMID 21109344, PMID 21135869, PMID 21871706, PMID 22017520, PMID 23234617, PMID 24119319, PMID 24571205, PMID 24938580, PMID 25353053, PMID 25712312, PMID 30680237, PMID 37415648
2008 (2), R01DK056199 (1)